Branch retinal vein occlusion and fluoxetine.

Ann Ophthalmol (Skokie)

Department of Ophthalmology, Rayne Institute, Kings' College London, St. Thomas' Hospital, London, SE1 7EH, UK.

Published: December 2007

A case of branch retinal vein occlusion associated with fluoxetine-induced secondary hypertension is described. Although an infrequent complication of selective serotonin reuptake inhibitor therapy, it is important that ophthalmologists are aware that these agents can cause hypertension because this class of drugs is widely prescribed.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12009-007-0026-5DOI Listing

Publication Analysis

Top Keywords

branch retinal
8
retinal vein
8
vein occlusion
8
occlusion fluoxetine
4
fluoxetine case
4
case branch
4
occlusion associated
4
associated fluoxetine-induced
4
fluoxetine-induced secondary
4
secondary hypertension
4

Similar Publications

Human Herpesvirus 6A Infection-Associated Acute Anterior Uveitis.

J Inflamm Res

December 2024

Department of Ophthalmology, the First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, 310003, People's Republic of China.

Human herpesvirus 6 (HHV-6) infection can cause ophthalmic diseases in immunocompetent patients, recipients of bone marrow transplants, and patients with acquired immunodeficiency syndrome (AIDS). This study describes the case of a healthy 37-year-old male who presented with unilateral anterior uveitis (AU), significant anterior chamber exudation, pupillary membrane closure, increased intraocular pressure, and eyelid edema. Notably, HHV-6A was the only pathogenic agent identified in the blood and aqueous humor.

View Article and Find Full Text PDF

Susac's syndrome is a rare inflammatory microangiopathy characterized by the triad of retinopathy, encephalopathy, and hearing loss. The syndrome causes recurrent microinfarcts in these organs, which in turn manifests with repeated attacks of visual field loss, hearing loss and tinnitus, and various brain syndromes. These often lead to the significant accumulation of disability over time, particularly if there is a delay or failure in diagnosis.

View Article and Find Full Text PDF

Background And Objective: Accurate extraction of retinal vascular components is vital in diagnosing and treating retinal diseases. Achieving precise segmentation of retinal blood vessels is challenging due to their complex structure and overlapping vessels with other anatomical features. Existing deep neural networks often suffer from false positives at vessel branches or missing fragile vessel patterns.

View Article and Find Full Text PDF

Background: We aimed to describe a 2-year outcome of eyes managed by practitioners benchmarked using a funnel plot by their frequency of treatment using vascular endothelial growth factor (VEGF) inhibitors for naive retinal vein occlusion (RVO).

Methods: A multicentre, international, observational study of 29 doctors in 12 countries managing 1110 eyes with RVO commencing VEGF inhibitors between 1 January 2012-2022 tracked in the Fight Retinal Blindness! registry.

Results: We identified 3 outlying 'intensive' practitioners (managing 350/1110 eyes [32%]), 22 'typical' practitioners (604/1110, [54%]) and 4 outlying 'relaxed' practitioners (156/1110, [14%]) with respective 24-month outcomes in Branch and Central RVO including the primary outcome, mean adjusted change in visual acuity (VA) in BRVO: +16.

View Article and Find Full Text PDF

Age-related macular degeneration (AMD) is a chronic multifactorial degenerative eye disease and one of the leading causes of irreversible blindness worldwide. Despite extensive research, there is no consensus on the predominant pathological mechanism leading to photoreceptor death. AMD is associated with molecular and cellular disruptions that ultimately result in photoreceptor degeneration.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!